Helus Pharma's HLP004 Phase 2: Small Study, Promising but Limited Signals

Helus Pharma's (Cybin/HELP) HLP004 Phase 2 trial shows potential adjunctive benefits in GAD but small size, 39% remission, no approval, injection format, and Phase 3 years away limit broad claims.